Home

Dawn Svoronos

CIK 1574579 · last filed 2026-09-03

Dawn Svoronos is a corporate insider who has filed 60 SEC Form 4 insider transactions across 7 companies since 2013. The most recent filing shows the insider exercised options covering $41.9K of XENE on Sep 3, 2026. Across all open-market trades the lifetime net is −$1.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.9M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$3.89M

Companies

7

Total Filings

60

Lifetime Open-Market Net

-$1.28M

Filer Profile

Reported Address
C/O MEDIVATION, INC.
525 MARKET ST., 36TH FLOOR
SAN FRANCISCO, CA 94105
Formerly Known As
Graham Dawn (2013–2013)
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
XENE Director 31,373 $59.75 $1.87M -$826.7K 14 2026-09-03
Adverum Biotechnologies, Inc. (ADVM) Delisted Director 0 $4.36 $0 $225.9K 9 2025-12-10
ACELYRIN, Inc. (SLRN) Delisted Director 15,000 $2.27 $34.0K $270.0K 2 2024-06-11
Global Blood Therapeutics, Inc. (GBT) Delisted Director 0 $68.49 $0 -$273.4K 7 2022-10-06
PTCT Director 29,017 $69.30 $2.01M $235.8K 12 2022-06-10
ENDOCYTE INC (ECYT) Delisted Director 0 — — $0 2 2018-12-21
MEDIVATION, INC. (MDVN) Delisted Director 21,206 — — -$910.9K 10 2016-06-23

Recent Filings

60 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-09-03 XENE Exer (M) +5,144 $41.9K EDGAR
2026-06-03 XENE Mixed +1,229 -$75.6K EDGAR
2025-12-10 Adverum Biotechnologies, Inc. (ADVM) Delisted Mixed −5,000 $0 EDGAR
2025-06-20 Adverum Biotechnologies, Inc. (ADVM) Delisted Grant (A) — $0 EDGAR
2025-06-06 XENE Grant (A) — $0 EDGAR
2025-05-23 — Disp (D) −15,000 $0
2024-06-20 Adverum Biotechnologies, Inc. (ADVM) Delisted Grant (A) — $0 EDGAR
2024-06-11 ACELYRIN, Inc. (SLRN) Delisted Grant (A) — $0 EDGAR
2024-06-05 XENE Grant (A) — $0 EDGAR
2023-08-24 XENE Sell (S) −25,000 -$967.5K EDGAR
Showing 1–10 of 60
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.